Duffield JS

Goodship JA

Goodship THJ

Kavanagh D

Kemp EJ

Mayland E

Richards A

Ward R

Warwick G

Winney RJ

Mutations in the plasma complement regulator factor H (CFH) and the transmembrane complement regulator membrane co-factor protein (MCP) have been shown to predispose to atypical hemolytic uremic syndrome (HUS). Both of these proteins act as co-factors for complement factor I (IF). IF is a highly specific serine protease that cleaves the α-chains of C3b and C4b and thus downregulates activation of both the classical and the alternative complement pathways. This study looked for IF mutations in a panel of 76 patients with HUS. Mutations were detected in two patients, both of whom had reduced serum IF levels. A heterozygous bp change, c.463 G &gt; A, which results in a premature stop codon (W127X), was found in one, and in the other, a heterozygous single base pair deletion in exon 7 (del 922C) was detected. Both patients had a history of recurrent HUS after transplantation. This is in accordance with the high rate of recurrence in patients with CFH mutations. Patients who are reported to have mutations in MCP, by contrast, do not have recurrence after transplantation. As with CFH- and MCP-associated HUS, there was incomplete penetrance in the family of one of the affected individuals. This study provides further evidence that atypical HUS is a disease of complement dysregulation. Copyright \ua9 2005 by the American Society of Nephrology

Newcastle University E-Prints

Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome

Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome

Abstract

Similar works

Full text

Available Versions

Newcastle University E-Prints